Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Sandra Malak, MD, Pascale Cony-Makhoul, MD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Philippe Rodon, MD, Fabienne Vacheret, MD, Barraco Fiorenza, MD, Francoise Boyer, MD, Katell Le Du, MD, Loic Garcon, MD PhD, Francois Lefrere, MD, Mathieu Wemeau, MD, Valerie Ugo, MD PhD, Jean-Jacques Kiladjian, MD PhD, Lydia Roy, MD

Blood (2016) 128 (22): 3123.

https://doi.org/10.1182/blood.V128.22.3123.3123

Published: 2016

Journal Articles

A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

Suporn Chuncharunee, MD, Nonglak Kanitsap, MD, Tawatchai Suwanban, MD, Archrob Khuhapinant, PhD MD, Noppacharn Uaprasert, MD, Kanchana Chansung, MD, Ekarat Rattarittamrong, MD, Somchai Wongkhantee, MD, Noppadol Siritanaratanakul, MD, Lalita Norasetthada, MD, Thanyaphong Na Nakorn, MD PhD, Chadchai Charnwiboonsri, Bsc.Pharm

Blood (2016) 128 (22): 5543.

https://doi.org/10.1182/blood.V128.22.5543.5543

Published: 2016

Journal Articles

One-Time Administration of Recombinant Human Erythropoietin Decreases B Cell in Human Peripheral Blood

Tomomi Nagashima, Akihiko Yokohama, MD PhD, Kie Nagai, Rumi Ino, Noriyuki Takahashi, Tetsuhiro Kasamatsu, Tomomi Sekigami, Hirono Iriuchishima, MD PhD, Makiko Takizawa, PhDMD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4899.

https://doi.org/10.1182/blood.V128.22.4899.4899

Published: 2016

Journal Articles

Tissue-Specific Regulation of Iron Release in Response to Body Iron Status Under Erythropoietic Stimulation

Yukari Matsuo-Tezuka, Mariko Noguchi-Sasaki, PhD, Mitsue Kurasawa, Keigo Yorozu, PhD, Yasushi Shimonaka

Blood (2015) 126 (23): 2148.

https://doi.org/10.1182/blood.V126.23.2148.2148

Published: 2015

Journal Articles

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Jeremy Monfray, CRA, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4477.

https://doi.org/10.1182/blood.V126.23.4477.4477

Published: 2015

Journal Articles

Iron Storage Rather Than Serum Iron Levels Is an Important Contributor to Iron-Induced Oxidative Stress Levels in Mice

Mariko Noguchi-Sasaki, PhD, Yusuke Sasaki, PhD, Yukari Matsuo-Tezuka, Mitsue Kurasawa, Keigo Yorozu, PhD, Yasushi Shimonaka

Blood (2015) 126 (23): 3362.

https://doi.org/10.1182/blood.V126.23.3362.3362

Published: 2015

Journal Articles

NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience

Virginie Chesnais, Aline Renneville, Andrea Toma, Veronique Sardnal, Marie Passet, Audrey Gauthier, Jacques Delaunay, MD, Aspasia Stamatoulas, MD, Odile Beyne-Rauzy, MDPhD, Pierre Fenaux, MD PhD, Francois Dreyfus, MD, Claude Preudhomme, PharmD, PhD, Olivier Kosmider, MD PhD, Michaela Fontenay

Blood (2014) 124 (21): 533.

https://doi.org/10.1182/blood.V124.21.533.533

Published: 2014

Journal Articles

Effectiveness Of Biosimilar Epoetin Alfa For The Treatment Of Chemotherapy-Induced Anemia In Patients With Hematological Malignancies

Samir G. Agrawal, Andrea Guy, Patricia O'Flaherty, Matthew Turner

Blood (2013) 122 (21): 3430.

https://doi.org/10.1182/blood.V122.21.3430.3430

Published: 2013

Journal Articles

Initial Change Of Iron Metabolic Flux Prior To Differentiation Of Erythroid Progenitors After Epoetin Beta Pegol (C.E.R.A.) Treatment

Yusuke Sasaki, Mariko Noguchi-Sasaki, Ph.D, Yukari Matsuo, Junko Fukumura, Fumi Sato-Inomata, Keigo Yorozu, Ph.D, Yasushi Shimonaka

Blood (2013) 122 (21): 3444.

https://doi.org/10.1182/blood.V122.21.3444.3444

Published: 2013

Journal Articles

Continuous Erythropoietin Receptor Activator Enhances Iron Metabolism by Hepcidin Down-Regulation and Maintains Stable Hemoglobin Levels by Controlling Maturation Rate of Erythroid-Lineage Cells

Yusuke Sasaki, Mariko Noguchi-Sasaki, Ph.D, Ken Aizawa, Ph.D, Yuki Matsumoto-Omori, Ph.D, Hirotaka Kanada, Keigo Yorozu, Ph.D, Yoshiyuki Moriguchi, Yasushi Shimonaka

Blood (2011) 118 (21): 1031.

https://doi.org/10.1182/blood.V118.21.1031.1031

Published: 2011

Journal Articles

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

David Sibon, Giovanna Cannas, Fiorenza Barraco, Thomas Prebet, M.D., Ph.D., Norbert Vey, MD, Anne Banos, MD, Caroline Besson, Selim Corm, Michel Blanc, Borhane Slama, Hervé Perrier, Pierre Fenaux, MD, PhD, Eric Wattel

Blood (2010) 116 (21): 4002.

https://doi.org/10.1182/blood.V116.21.4002.4002

Published: 2010

Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Blood (2010) 116 (21): 1880.

https://doi.org/10.1182/blood.V116.21.1880.1880

Published: 2010

Journal Articles

Intravenous Iron Supplementation for the Treatment of Cancer-Related Anemia – Systematic Review and Meta-Analysis

Anat Gafter-Gvili, MD, Benaya Rozen-Zvi, MD, Liat Vidal, MD, Uzi Gafter, MD, PHD, Johan F. Vansteenkiste, MD, Ofer Shpilberg, MD, MPH

Blood (2010) 116 (21): 4249.

https://doi.org/10.1182/blood.V116.21.4249.4249

Published: 2010

Journal Articles

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools

Pradeep Sathyanarayana, Estelle Houde, Deborah Marshall, Amy Volk, Dorie Makropoulos, Christine Emerson, Anamika Pradeep, Peter J. Bugelski, Don M. Wojchowski

Blood (2009) 113 (20): 4955–4962.

https://doi.org/10.1182/blood-2008-08-172320

Published: 2009

Includes: Supplemental data

Journal Articles

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Julia Bohlius, MD, MScPH, Corinne Brillant, Michael Clarke, PhD, Sabine Kluge, Maryann Napoli, Margaret Piper, PhD, MPH, Dirk Rades, MD, PhD, Isabelle Ray-Coquard, MD, Kurt Schmidlin, MD, MPH, Martin Schumacher, PhD, Guido Schwarzer, PhD, Jerome Seidenfeld, MSc, PhD, David P. Steensma, MD, FACP, Sven Trelle, MD, Michael Untch, MD, Olaf Weingart, MD, Marcel Zwahlen, PhD, Matthias Egger, MD, MSc, Andreas Engert, MD

Blood (2008) 112 (11): lba-6.

https://doi.org/10.1182/blood.V112.11.lba-6.lba-6

Published: 2008

Journal Articles

An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

Gregor Verhoef, MD, Hans E Johnsen, MD, Francesca Gaia Rossi, MD, Antonio Salar, MD, PhD, Lisa Hamilton, MSc, W. Marieke Schoonen, PhD, Beatriz Pujol, PhD, Ulrich Duhrsen, MD

Blood (2008) 112 (11): 4948.

https://doi.org/10.1182/blood.V112.11.4948.4948

Published: 2008

Journal Articles

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

H. Tilman Steinmetz, Antonis Georg Tsamaloukas, MD, PhD, Stephan Schmitz, Jörg Wiegand, Robert Rohrberg, Jochen Eggert, Heidi Eustermann, Hans-Werner Tessen, Lothar Thomas

Blood (2008) 112 (11): 4578.

https://doi.org/10.1182/blood.V112.11.4578.4578

Published: 2008

Journal Articles

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Carsten Bokemeyer, Pierre Soubeyran, Matti Aapro, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4706.

https://doi.org/10.1182/blood.V112.11.4706.4706

Published: 2008

Journal Articles

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Pierre Soubeyran, Matti Aapro, Carsten Bokemeyer, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4672.

https://doi.org/10.1182/blood.V112.11.4672.4672

Published: 2008

Journal Articles

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Heinz Ludwig, Matti Aapro, Carsten Bokemeyer, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, Karen MacDonald, Tara Albrecht, Ivo Abraham

Blood (2008) 112 (11): 4715.

https://doi.org/10.1182/blood.V112.11.4715.4715

Published: 2008

NARROW

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

One-Time Administration of Recombinant Human Erythropoietin Decreases B Cell in Human Peripheral Blood

Tissue-Specific Regulation of Iron Release in Response to Body Iron Status Under Erythropoietic Stimulation

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Iron Storage Rather Than Serum Iron Levels Is an Important Contributor to Iron-Induced Oxidative Stress Levels in Mice

NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience

Effectiveness Of Biosimilar Epoetin Alfa For The Treatment Of Chemotherapy-Induced Anemia In Patients With Hematological Malignancies

Initial Change Of Iron Metabolic Flux Prior To Differentiation Of Erythroid Progenitors After Epoetin Beta Pegol (C.E.R.A.) Treatment

Continuous Erythropoietin Receptor Activator Enhances Iron Metabolism by Hepcidin Down-Regulation and Maintains Stable Hemoglobin Levels by Controlling Maturation Rate of Erythroid-Lineage Cells

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Intravenous Iron Supplementation for the Treatment of Cancer-Related Anemia – Systematic Review and Meta-Analysis

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only